Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Declines By 50.0%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant decrease in short interest in May. As of May 31st, there was short interest totalling 1,000 shares, a decrease of 50.0% from the May 15th total of 2,000 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 185,900 shares, the short-interest ratio is currently 0.0 days.

Vincerx Pharma Stock Down 6.5%

Vincerx Pharma stock opened at $0.06 on Friday. The company has a 50 day moving average of $0.10 and a 200-day moving average of $1.61. The stock has a market capitalization of $287,870.00, a PE ratio of 0.00 and a beta of 1.75. Vincerx Pharma has a twelve month low of $0.04 and a twelve month high of $17.17.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.